Phase I trial of OMS 824 binding activity to PDE 10 in brains of healthy volunteers.

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 09 Apr 2014

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Apr 2014 Early findings will be presented at the 2014 Biennial Conference of the Schizophrenia International Research Society (SIRS) according to an Omeros Corporation media release.
11 Feb 2014 Since the maximum tolerated dose has not been reached in the latest cohort, Omeros is now planning to evaluate a higher dose of OMS 824 in the trial to determine whether a higher level of PDE10 occupancy can be achieved, according to a media release.
11 Feb 2014 Additional positive results published in an Omeros Corporation media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com